The tradition of general health and science information has long served as a foundation for public understanding, bridging clinical practice and community education. Historically, such knowledge has been disseminated through institutional channels, including hospital career portals and health outreach programs, which emphasize the importance of accessible, accurate medical guidance. This heritage underscores a commitment to translating complex biomedical concepts into actionable insights for diverse audiences, from patients to healthcare professionals. Within this tradition, the systematic classification of diseases has been a cornerstone, enabling standardized communication across clinical and research settings. The International Classification of Diseases (ICD) coding system exemplifies this effort, providing a structured framework for documenting diagnoses and health conditions.
As this informational landscape evolves, the focus naturally extends beyond general wellness to encompass the nuanced interplay between therapeutic interventions and patient outcomes. In particular, the documentation of pharmaceutical effects—both intended and unintended—has become a critical area of inquiry, requiring precise terminology to capture potential risks. This pivot from broad health literacy to a more targeted concern arises in occupational contexts, where workers may encounter pharmacological agents as part of their environment. Here, the transition from general health information to exposure-related risk assessment becomes salient. The coding of adverse health effects, such as those potentially linked to pharmaceutical exposure, demands rigorous attention to classification accuracy.
Autoimmune hepatitis (AIH) is a chronic, immune-mediated inflammatory disease of the liver characterized by elevated serum transaminases, the presence of autoantibodies (e.g., antinuclear antibody, smooth muscle antibody), elevated immunoglobulin G levels, and interface hepatitis on liver biopsy. The clinical presentation is variable, ranging from asymptomatic transaminase elevation to acute liver failure. Common symptoms include fatigue, jaundice, abdominal pain, and arthralgia. Diagnosis requires exclusion of other causes of liver disease, including viral hepatitis, alcohol-induced injury, and drug-induced liver injury. The distinction between drug-induced autoimmune-like hepatitis and idiopathic AIH is clinically challenging and often relies on the temporal relationship between drug exposure and disease onset, as well as response to immunosuppressive therapy.
Pharmaceutical agents are a recognized trigger for autoimmune hepatitis. The mechanism is not fully understood but is believed to involve molecular mimicry, haptenization of hepatic proteins, or immune dysregulation in genetically susceptible individuals. Drugs most commonly implicated include minocycline, nitrofurantoin, methyldopa, hydralazine, and biologic agents such as tumor necrosis factor-alpha inhibitors. The latency period between drug initiation and onset of AIH can range from weeks to several years, depending on the agent and individual patient factors. For example, minocycline-associated AIH typically presents after months to years of continuous use, whereas nitrofurantoin-induced hepatitis may occur after a shorter exposure. The clinical and histologic features of drug-induced AIH are often indistinguishable from idiopathic AIH, making causality assessment essential.
The pathogenic pathway involves drug-induced hepatocyte injury leading to the release of autoantigens, activation of CD4+ T cells, and subsequent B-cell activation with autoantibody production. Genetic predisposition, particularly involving the HLA-DR3 and HLA-DR4 alleles, increases susceptibility. The immune response is directed against liver-specific antigens, such as asialoglycoprotein receptor and cytochrome P450 2D6. In drug-induced cases, the drug or its reactive metabolite may alter self-antigens, breaking immune tolerance. Cessation of the offending drug often leads to clinical improvement, but some patients require immunosuppressive therapy, and a subset may progress to cirrhosis or liver failure.
Regulatory safety communications and product labeling highlight the risk of autoimmune hepatitis as an adverse reaction for specific pharmaceuticals. For instance, the prescribing information for minocycline includes warnings about hepatotoxicity, including autoimmune hepatitis, and advises monitoring for signs of liver injury. Similarly, nitrofurantoin labeling warns of acute and chronic hepatic reactions, including autoimmune hepatitis, particularly in patients on long-term therapy. Healthcare professionals are advised to discontinue the suspected drug upon evidence of liver injury and to consider referral for specialist evaluation. Patients should be counseled on the symptoms of hepatitis, such as dark urine, jaundice, and right upper quadrant pain, and instructed to seek medical attention if these occur. (https://dailymed.nlm.nih.gov/dailymed/index.cfm)
For clinical documentation and coding purposes, the ICD-10-CM code for autoimmune hepatitis is K75.4 (Autoimmune hepatitis). When the condition is attributable to a pharmaceutical agent, an additional code from the T36-T50 range (Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances) should be assigned to identify the specific drug and the adverse effect. For example, adverse effect of minocycline would be coded as T36.4X5A (Adverse effect of tetracyclines, initial encounter). The external cause code should be sequenced as the primary diagnosis when the adverse effect is the reason for the encounter, followed by the manifestation code K75.4. For chronic or subsequent encounters, the appropriate seventh character (D for subsequent encounter, S for sequela) should be applied. Pathology coding may include liver biopsy findings, such as interface hepatitis, which is documented descriptively. Genetic testing for HLA-DR3 or HLA-DR4 is not typically coded separately but may be noted in the medical record. CPT codes for liver biopsy (e.g., 47000, 47001) and relevant laboratory tests (e.g., autoantibody panels) may be applicable.
The timeline between pharmaceutical exposure and the onset of autoimmune hepatitis varies widely. For some drugs, such as nitrofurantoin, the onset may occur after months of therapy, while for others, such as minocycline, it may occur after years. In rare cases, symptoms may appear shortly after drug initiation. The latency period is an important factor in causality assessment. After drug discontinuation, clinical improvement is often observed within weeks to months, but some patients may experience persistent disease requiring long-term immunosuppression. Progression to cirrhosis can occur over years, particularly if the diagnosis is delayed or the offending drug is continued. Documenting the start and stop dates of the pharmaceutical agent is critical for accurate coding and for establishing a causal relationship in the medical record.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
| Field | Value |
|---|---|
| ICD-10-CM Code | K75.4 |
| Descriptor | Autoimmune hepatitis |
| Billable | Yes |
| Includes | Lupoid hepatitis not elsewhere classified |
| Excludes1 | Chronic active hepatitis (K73.9) |
| Excludes2 | Autoimmune hepatitis with cirrhosis (K74.69) |
| Adverse effect coding | Use additional code from T36-T50 to identify drug |
| Seventh character | A (initial), D (subsequent), S (sequela) |
| CPT for liver biopsy | 47000, 47001 |
| Lab tests | Autoantibody panel (e.g., ANA, SMA) |
The ICD-10-CM code for autoimmune hepatitis is K75.4. This code is used to document the diagnosis of autoimmune hepatitis in medical records and billing.
When a drug causes autoimmune hepatitis, assign code K75.4 for the condition and an additional code from the T36-T50 range to identify the specific drug and adverse effect. For example, adverse effect of minocycline is coded as T36.4X5A. Sequence the adverse effect code first if it is the reason for the encounter.
Drug-induced autoimmune hepatitis is triggered by a medication and often improves after discontinuation, while idiopathic AIH has no known trigger. Both share similar clinical and histologic features, but causality assessment relies on temporal relationship and response to drug withdrawal.
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.